Therefore, we can design the targeted molecules based on the ligand binding site to reduce osteonecrosis by competitively occupying the original binding site with ZOL and stabilizing the trimerization of RANKL (Ostrem et al., 2013; De Vita et al., 2019). The gene discussed is TNFSF11; the disease is osteonecrosis.